Hermetica Superfood Encyclopedia
The Short Answer
Schizophyllum commune produces schizophyllan, a triple-helical β-1,3/1,6-glucan polysaccharide that binds β-glucan receptors (Dectin-1) on innate immune cells to enhance phagocytic activity and modulate cytokine cascades, alongside phenolics and terpenoids that scavenge reactive oxygen species and inhibit pro-inflammatory pathways. Preclinical data indicate that ethanolic extracts at 500 µg/ml reduce lymphocyte DNA damage to 3.5 ± 0.71%, while a 10 mg dose in BPA-exposed fish models decreased micronuclei frequency by 81% and increased catalase activity by 35.2%, reflecting meaningful antigenotoxic and antioxidant potency in controlled settings.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordSchizophyllum commune benefits
Split Gill Mushroom — botanical close-up
Health Benefits
**Immunomodulation via β-Glucan Activity**
Schizophyllan (SPG) binds Dectin-1 and complement receptor 3 (CR3) on macrophages and natural killer cells, upregulating phagocytic activity and cytokine production; animal studies report enhanced survival against Sendai virus and white spot syndrome virus in shrimp models treated with SPG.
**Antioxidant and Antigenotoxic Protection**
Ethanolic and methanolic extracts scavenge DPPH radicals (IC50 ~50.61 µg/ml), ABTS radicals (IC50 ~198 µg/ml), and chelate ferrous ions (IC50 ~2.62 mg/ml), while reducing DNA strand breaks in human lymphocytes and fish erythrocytes by up to 78.7% in comet assay measurements.
**Anti-inflammatory Activity**
Phenolic compounds including hydroxybenzoic acid and protocatechuic acid, together with terpenoids such as squalene and trans-geranylgeraniol identified by GC-MS, suppress inflammatory mediator pathways by inhibiting lipid peroxidation and modulating oxidative enzyme activity.
**Anticancer Potential**: Iminolactone derivatives isolated from S
commune suppress cancer cell proliferation in vitro, while schizophyllan's immunostimulatory β-glucan backbone activates innate immune surveillance mechanisms that may contribute to antineoplastic defense; these effects remain confined to preclinical models.
**Antidiabetic Properties**
Phenolic constituents and β-glucan polysaccharides have demonstrated inhibitory effects on α-glucosidase and related carbohydrate-metabolizing enzymes in preclinical screens, with the high bioactive carbohydrate content (25.15 ± 0.005% dry weight) contributing to postprandial glucose modulation potential.
**Antimicrobial and Antibacterial Effects**
Methanolic and ethanolic extracts exhibit activity against a range of bacterial pathogens attributed to membrane-disrupting terpenoids and phenolic chelation of metal cofactors required by bacterial enzymes, though minimum inhibitory concentrations vary substantially by extraction solvent and pathogen strain.
**Nutritional and Adaptogenic Support**
The fruiting body provides ergosterol (a provitamin D2 precursor), tocopherols, and a broad mineral and vitamin profile alongside macronutrients, positioning S. commune as a functional food ingredient capable of supporting metabolic resilience in addition to its direct bioactive effects.
Origin & History
Natural habitat
Schizophyllum commune is one of the most widely distributed fungi on Earth, found on dead or decaying wood across tropical, subtropical, and temperate regions spanning Africa, Asia, the Americas, and Europe. It grows saprotrophically on hardwood and softwood substrates in humid forest environments, fruiting year-round in warm climates and seasonally in cooler zones. Traditional cultivation and collection occur predominantly in parts of Southeast Asia, West Africa, and Central America, where it is gathered from the wild or cultivated on lignocellulosic substrates in submerged mycelial culture systems.
“Schizophyllum commune has been consumed as a food and folk medicine across sub-Saharan Africa, Southeast Asia (particularly Thailand, Malaysia, and the Philippines), and parts of Latin America for centuries, prized for its availability on decaying wood and its attributed antineoplastic, antibacterial, and antiparasitic properties. In traditional West African ethnomedicine, dried fruiting bodies were prepared as decoctions and administered for gastrointestinal ailments and systemic infections, while in parts of Southeast Asia the mushroom is eaten fresh or dried as a nutritious side dish without formal medicinal preparation. Japanese researchers in the mid-to-late twentieth century isolated and characterized schizophyllan as a biological response modifier, leading to its registration as the pharmaceutical agent sizofilan (SPG) for use as an immunopotentiating adjuvant in cervical cancer radiotherapy protocols in Japan. The species holds the distinction of being one of the most genetically diverse eukaryotes studied, with over 28,000 distinct mating types documented, a biological curiosity that has made it a model organism in fungal genetics alongside its medicinal and nutritional relevance.”Traditional Medicine
Scientific Research
The current evidence base for Schizophyllum commune is composed almost entirely of in vitro cell culture assays, ex vivo human lymphocyte genotoxicity models, and small animal studies (fish, shrimp, and rodent models), with no published randomized controlled trials in human subjects reported as of the available literature. Preclinical highlights include comet assay data in BPA-exposed fish demonstrating 65.5% reduction in tail length and 81% reduction in micronuclei frequency at a 10 mg extract dose, and in vitro human lymphocyte data showing residual DNA damage of only 3.5 ± 0.71% at 500 µg/ml ethanolic extract. Antioxidant characterization studies provide reproducible IC50 values across multiple radical scavenging assays (DPPH IC50 ~50.61 µg/ml; ABTS IC50 ~198 µg/ml; superoxide IC50 ~1.503 mg/ml), lending reasonable confidence to antioxidant claims but not translating directly to clinical bioavailability. The immunomodulatory and antiviral data for schizophyllan derive from murine and crustacean infection models; while schizophyllan has been investigated in Japan as an adjunct to cervical cancer radiotherapy (sizofilan), comprehensive multi-center RCT data with standardized endpoints are not widely accessible in the international literature, substantially limiting the overall evidence grade.
Preparation & Dosage
Traditional preparation
**Ethanolic/Methanolic Extract (Research Grade)**
Used at 250–500 µg/ml in in vitro cytotoxicity and antioxidant assays; no equivalent standardized human oral dose has been established.
**Polysaccharide Fraction (Schizophyllan/Sizofilan)**
Administered as an injectable adjuvant in Japanese oncology settings at investigational doses; oral bioavailability of the native triple-helical polymer is low due to gastric degradation and limited intestinal absorption.
**Dried Fruiting Body Powder**
Consumed as a food ingredient or encapsulated supplement in traditional Asian and African culinary contexts; no standardized dose or minimum effective concentration has been defined for human supplementation.
**Submerged Mycelial Culture Extracts (Exopolysaccharides)**
Produced commercially for research applications; concentration expressed as mg polysaccharide per mL of culture broth, not yet translated to dosage units for consumer products.
**Traditional Preparation**
Fruiting bodies consumed raw or dried and incorporated into soups, stews, and broths; methanolic and water decoctions used in folk medicine for anti-inflammatory and antiparasitic applications.
**Standardization Note**
No commercial supplement standard for schizophyllan content (% w/w) has been broadly adopted; consumers should seek products specifying β-glucan content as a proxy quality marker.
**Timing**
No pharmacokinetic data exist to guide timing of administration relative to meals or other supplements.
Nutritional Profile
Schizophyllum commune fruiting bodies contain high moisture content (approximately 60.60 ± 0.122% fresh weight) and, on a dry weight basis, are characterized by elevated bioactive carbohydrates including β-glucan polysaccharides (total carbohydrates ~25.15 ± 0.005% dry weight). Phenolic content is relatively modest at approximately 1.27 ± 0.06 mg gallic acid equivalents per gram of ethanolic extract, while flavonoid content is substantially higher at 17.18 ± 0.054 mg rutin equivalents per gram, suggesting flavonoids are a dominant antioxidant class. Ergosterol serves as a provitamin D2 precursor activated by UV exposure; tocopherols contribute to lipid-soluble antioxidant capacity; and GC-MS analysis has identified volatile and semi-volatile terpenoids including squalene, trans-geranylgeraniol, n-heptadecanol-1, and 3-n-propyl-2,4-pentanedione. Mineral and vitamin profiles typical of wood-decomposing basidiomycetes include potassium, phosphorus, magnesium, iron, zinc, and B-complex vitamins, though exact concentrations vary with substrate, geographic origin, and harvest maturity; bioavailability of polysaccharides is constrained by the chitinous cell wall matrix, which may require cooking or extraction to improve digestibility.
How It Works
Mechanism of Action
Schizophyllan, the primary β-1,3-glucan with β-1,6-linked side chains produced by S. commune, adopts a triple-helical conformation in aqueous solution that is recognized by pattern recognition receptors—principally Dectin-1 and complement receptor CR3—on monocytes, macrophages, and dendritic cells, triggering NF-κB and MAPK signaling cascades that enhance phagocytosis, reactive oxygen species generation within phagolysosomes, and pro-inflammatory cytokine (TNF-α, IL-1β, IL-6) secretion followed by regulatory cytokine normalization. Phenolic acids such as protocatechuic acid and hydroxybenzoic acid donate hydrogen atoms to quench peroxyl and hydroxyl radicals directly, while also chelating redox-active ferrous iron to suppress Fenton-type oxidative chain reactions; these same compounds contribute to upregulation of endogenous antioxidant enzymes including superoxide dismutase, catalase (activity increased ~35.2% in treated fish models), and glutathione reductase. GC-MS-identified terpenoids—including squalene and trans-geranylgeraniol—interfere with membrane fluidity and inhibit lipid peroxidation cascades, while iminolactone derivatives disrupt cell cycle progression in neoplastic cells through mechanisms likely involving topoisomerase inhibition or alkylating interactions with DNA replication machinery. Collectively, these multi-target pathways explain the observed dose-dependent reductions in comet assay tail DNA percentage, micronuclei frequency, and oxidative stress biomarkers across in vitro and animal model systems.
Clinical Evidence
No large-scale, peer-reviewed randomized controlled trials in human volunteers have been published characterizing the clinical efficacy or safety of Schizophyllum commune extracts or isolated schizophyllan across the general population. Sizofilan (purified schizophyllan) has been studied in Japan as an immunopotentiating adjuvant in cervical cancer patients undergoing radiotherapy, with some reports of improved immune parameters, but these studies have not been replicated in large multi-center designs with standardized reporting of effect sizes, confidence intervals, or patient-reported outcomes. The most quantitatively robust data available originate from controlled in vitro and animal experiments: 81% micronuclei reduction and 35.2% catalase upregulation in fish models, and near-complete protection from induced DNA strand breaks in human lymphocyte cultures. Confidence in translating these findings to human clinical outcomes remains low until pharmacokinetic studies, dose-escalation trials, and double-blind RCTs are conducted; the ingredient should currently be regarded as biologically promising but clinically unvalidated.
Safety & Interactions
At concentrations up to 500 µg/ml in human lymphocyte cultures and at 10 mg doses in fish models, S. commune extracts produced no evidence of intrinsic genotoxicity or overt cytotoxicity, and the species is widely consumed as food across multiple cultures without documented acute toxicity; however, formal toxicological characterization including LD50 determination, subchronic oral toxicity studies, and allergenicity profiling in human subjects has not been published in accessible peer-reviewed literature. Individuals with compromised immune systems or those receiving immunosuppressive therapy (e.g., calcineurin inhibitors, corticosteroids, or biologic agents such as TNF-α inhibitors) should exercise caution given schizophyllan's established immunostimulatory activity, which could theoretically antagonize immunosuppression or provoke immune dysregulation. S. commune is an opportunistic pathogen in severely immunocompromised individuals (case reports of sinusitis and pulmonary infection in AIDS patients and transplant recipients exist in the medical literature), representing a direct contraindication to consumption in high-dose extract or supplemental form for this population. No pregnancy- or lactation-specific safety data have been published; standard precautionary guidance advises avoidance of concentrated extracts during pregnancy pending safety evaluation, while culinary consumption at traditional food quantities is unlikely to pose risk based on historical use patterns.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Schizophyllum commune Fr.Split Gill MushroomSizofilanSchizophyllan (SPG)Common Split GillSchizopora commune
Frequently Asked Questions
What is schizophyllan and what does it do in the body?
Schizophyllan (SPG or sizofilan) is a triple-helical β-1,3/1,6-glucan polysaccharide secreted by Schizophyllum commune that binds the Dectin-1 and CR3 pattern recognition receptors on macrophages and dendritic cells, triggering NF-κB signaling to enhance phagocytosis and cytokine-mediated immune responses. In Japanese clinical oncology, purified schizophyllan has been used as an immunopotentiating adjuvant alongside cervical cancer radiotherapy, and in animal models it significantly increased survival rates against viral infections; however, its oral bioavailability is low because the triple-helical structure is partially denatured and degraded in the gastrointestinal tract before systemic absorption.
Is Schizophyllum commune safe to eat or supplement with?
As a food, S. commune is widely consumed across Africa, Southeast Asia, and Latin America without documented acute toxicity, and controlled in vitro studies at 500 µg/ml and fish-model doses of 10 mg show no genotoxic effects. However, it is an established opportunistic pathogen in severely immunocompromised individuals—including those with advanced HIV/AIDS, organ transplant recipients, or patients on high-dose corticosteroids—in whom it has caused sinus and pulmonary infections, making supplemental high-dose extract use contraindicated in these groups; otherwise healthy individuals considering concentrated supplements should consult a physician, particularly if taking immunosuppressive medications.
What is the recommended dosage of Schizophyllum commune extract?
No standardized human oral dosage has been established for S. commune extracts or isolated schizophyllan in peer-reviewed guidelines. Preclinical research has used concentrations of 250–500 µg/ml in cell culture models and 5–10 mg in fish genotoxicity models; the injectable sizofilan used in Japanese oncology was dosed at investigational levels not directly translatable to oral supplementation. Until pharmacokinetic and dose-ranging clinical trials are completed, no specific daily dose can be recommended with confidence.
Does Schizophyllum commune have proven anticancer effects in humans?
Currently, there are no published large-scale randomized controlled trials in humans confirming anticancer efficacy of S. commune extracts or schizophyllan. Sizofilan has been investigated in Japan as an immune adjuvant in cervical cancer radiotherapy with some reports of immune parameter improvement, and in vitro studies show that iminolactone derivatives and β-glucan fractions suppress cancer cell proliferation, but these findings have not been validated in rigorous multi-center human trials. The anticancer evidence must therefore be considered preliminary and preclinical until further clinical research is conducted.
How does Schizophyllum commune compare to other medicinal mushrooms like reishi or lion's mane?
Schizophyllum commune shares the β-glucan immunomodulatory mechanism common to medicinal mushrooms like Ganoderma lucidum (reishi) and Hericium erinaceus (lion's mane), but its primary distinctive compound—schizophyllan—is a structurally unique triple-helical homopolymer not found in other species, and it has been more specifically investigated as an oncology adjuvant rather than for the neuroprotective (lion's mane NGF induction) or adaptogenic (reishi triterpenes) properties of those species. Evidence quality for S. commune in humans is currently lower than for reishi or lion's mane, which have more extensive clinical trial datasets; S. commune's greatest evidence strength lies in its antioxidant and antigenotoxic activity in cellular and animal models, where its phenolic and flavonoid fractions perform comparably to other phenolic-rich medicinal fungi.
What is the difference between Schizophyllum commune extract and whole mushroom powder?
Schizophyllum commune extracts are typically standardized to contain higher concentrations of bioactive β-glucans (schizophyllan/SPG), whereas whole mushroom powder contains the full spectrum of compounds but at lower and variable potencies. Extracts undergo processing to concentrate the immunomodulatory polysaccharides responsible for Dectin-1 and CR3 receptor activation, making them more efficient for supplementation purposes. The choice between extract and powder depends on whether you prioritize concentrated bioactive dosing or whole-food nutritional profile.
Can Schizophyllum commune interact with immunosuppressant medications?
Schizophyllum commune may theoretically interact with immunosuppressant drugs since schizophyllan enhances macrophage and natural killer cell activity, potentially counteracting the intended effects of immunosuppressive therapy. Individuals taking medications for autoimmune conditions, organ transplant recipients, or those on corticosteroid-based immunosuppression should consult a healthcare provider before supplementing with this mushroom. The immunomodulatory mechanism, while beneficial for some, could be contraindicated in these specific clinical contexts.
Is there clinical evidence that Schizophyllum commune supports immune function in humans?
While animal studies demonstrate that schizophyllan (SPG) enhances immune responses against viral infections and increases phagocytic activity in macrophages, human clinical trials remain limited and predominantly focus on cancer-adjuvant applications rather than general immune support. Most human evidence involves SPG as an immunopotentiator combined with chemotherapy rather than as standalone immune enhancement in healthy populations. The translation from animal immunology data to proven human immune benefits requires further rigorous clinical investigation.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w schizophyllum-commune-split-gill-mushroom curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
